MacroGenics, Incyte's PD-1 med to face off with Merck's Keytruda in a first for cancer R&D

armwrestle
The study’s main objective isn’t to challenge Keytruda with a new PD-1 drug; it’s actually designed to gauge how MacroGenics’ anti-B7-H3 med enoblituzumab fares against standard of care, in combination with its Incyte-partnered PD-1 drug MGA012 and chemotherapy, as well as with MGA012 alone. (Ryan McGuire/Pixabay)

It has the makings of a David and Goliath story: MacroGenics will kick off a trial later this year that will pit its Incyte-partnered anti-PD-1 drug against Merck’s Keytruda—the first drug of its class to win approval—in patients with head and neck cancer. 

To be clear, the study’s main objective isn’t to challenge Keytruda with a new PD-1 drug, Evercore ISI analysts Jonathan Miller and Umer Raffat wrote in a note on Wednesday. It’s actually designed to gauge how MacroGenics’ anti-B7-H3 med enoblituzumab fares against standard of care, in combination with its Incyte-partnered PD-1 drug MGA012 and chemotherapy, as well as with MGA012 alone. 

But by using Keytruda with chemo as the standard-of-care arm and including another arm that will test MGA012 with chemo, MacroGenics will come out of the trial with a head-to-head battle between a new PD-1-targeting antibody and Merck’s blockbuster Keytruda. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

It is, by the analysts' reckoning, the first time a study has done this. 

RELATED: Keytruda's 'wall of data' bodes well for Merck's future growth: exec

“This trial pits a new PD-1 vs Keytruda, directly compared. To our knowledge, this is the first trial we've found that is attempting this comparison,” they said in the note. 

The phase 2 study will recruit 200 patients with head and neck cancer, with 50 patients in each arm, the analysts wrote. It will test enoblituzumab and MGA012 in patients who have not undergone other treatments. 

For its part, Keytruda has beat its rival, Opdivo from Bristol-Myers Squibb, to be the first PD-1 med approved for untreated head-and-neck-cancer patients. Both drugs had FDA nods in later-line settings, but Keytruda pulled ahead this year, after posting promising data at last year’s European Society for Medical Oncology annual meeting and snagging a priority review tag from the FDA. 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.